Covered recipient · General Payments record
PHILLIP B GORELICK
Allopathic & Osteopathic Physicians Psychiatry & Neurology Vascular Neurology
General Payments · PY2018–2024
$296,863.23
- Reported across 251 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Consulting Fee | $38,903.50 | 34 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $27,248.00 | 15 |
| AstraZeneca UK Limited | $4,240.50 | 7 |
| UCB SA | $4,040.00 | 10 |
| Amgen Inc. | $3,375.00 | 2 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (34)
Sorted by paying entity, then date · as published by CMS
Program year 2024 201820192020202120222023
Record-level detail is published for PY2024; earlier years are summarised in
“By program year”.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| Amgen Inc. | $1,625.00 | 05/28/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1115672238 | CMS |
| Amgen Inc. | $1,750.00 | 12/03/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1115672246 | CMS |
| AstraZeneca UK Limited | $250.00 | 01/10/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1093918721 | CMS |
| AstraZeneca UK Limited | $805.50 | 02/07/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1093978719 | CMS |
| AstraZeneca UK Limited | $805.50 | 04/08/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1093914094 | CMS |
| AstraZeneca UK Limited | $500.00 | 04/10/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1093933035 | CMS |
| AstraZeneca UK Limited | $805.50 | 05/20/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1093927190 | CMS |
| AstraZeneca UK Limited | $537.00 | 07/15/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1094050596 | CMS |
| AstraZeneca UK Limited | $537.00 | 09/19/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1094000296 | CMS |
| E.R. Squibb & Sons, L.L.C. | $620.00 | 01/19/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1101355094 | CMS |
| E.R. Squibb & Sons, L.L.C. | $1,581.00 | 02/22/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1101355104 | CMS |
| E.R. Squibb & Sons, L.L.C. | $1,302.00 | 03/20/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1101355108 | CMS |
| E.R. Squibb & Sons, L.L.C. | $3,038.00 | 04/01/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1101355112 | CMS |
| E.R. Squibb & Sons, L.L.C. | $2,139.00 | 04/11/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1101355118 | CMS |
| E.R. Squibb & Sons, L.L.C. | $1,754.60 | 05/01/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1101355126 | CMS |
| E.R. Squibb & Sons, L.L.C. | $2,281.60 | 06/07/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1101355136 | CMS |
| E.R. Squibb & Sons, L.L.C. | $1,847.60 | 07/11/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1101355146 | CMS |
| E.R. Squibb & Sons, L.L.C. | $620.00 | 07/17/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1101355148 | CMS |
| E.R. Squibb & Sons, L.L.C. | $2,542.00 | 08/12/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1101355152 | CMS |
| E.R. Squibb & Sons, L.L.C. | $3,317.00 | 10/02/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1101355158 | CMS |
| E.R. Squibb & Sons, L.L.C. | $3,174.40 | 10/17/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1101355170 | CMS |
| E.R. Squibb & Sons, L.L.C. | $1,382.60 | 11/08/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1101355176 | CMS |
| E.R. Squibb & Sons, L.L.C. | $998.20 | 12/10/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1101355178 | CMS |
| E.R. Squibb & Sons, L.L.C. | $650.00 | 12/16/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1101355182 | CMS |
| UCB SA | $1,140.00 | 02/09/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1113950959 | CMS |
| UCB SA | $125.00 | 03/01/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1113950941 | CMS |
| UCB SA | $125.00 | 03/28/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1113950943 | CMS |
| UCB SA | $600.00 | 04/26/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1113950955 | CMS |
| UCB SA | $500.00 | 06/21/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1113950953 | CMS |
| UCB SA | $250.00 | 07/26/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1113950947 | CMS |
| UCB SA | $310.00 | 08/30/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1113950951 | CMS |
| UCB SA | $600.00 | 10/04/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1113950957 | CMS |
| UCB SA | $125.00 | 10/25/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1113950945 | CMS |
| UCB SA | $265.00 | 11/29/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1113950949 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2018, 2019, 2020, 2021, 2022, 2023, 2024
- Source files
- Dataset page · Bulk file · PY2018 , PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.